In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors. Featured Articles: Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment Plasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolism Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer
